[Form 4] Organon & Co. Insider Trading Activity

Rhea-AI Filing Summary

Organon & Co. executive Vittorio Nisita reported routine equity compensation activity. On March 31, 2026, Nisita received a grant of 125,208 Restricted Stock Units (RSUs), each representing a contingent right to one share of Organon common stock. These RSUs will vest in three equal installments on March 31, 2027, 2028, and 2029.

On the same date, portions of earlier RSU grants from 2023 and 2025 vested, converting into a total of 13,000 shares of common stock. To satisfy tax obligations, 4,453 shares were withheld at a reference price of $5.70 per share, leaving Nisita with 70,619.158 common shares held directly after these transactions.

Insider Trade Summary

13,000 shares exercised/converted

Mixed 7 txns

Insider Nisita Vittorio

Role Head of Global Business Svcs

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	125,208	$0.00	--
Exercise	Restricted Stock Units	4,606	$0.00	--
Exercise	Restricted Stock Units	8,394	$0.00	--
Exercise	Common Stock	4,606	$0.00	--
Tax Withholding	Common Stock	1,578	$5.70	$9K
Exercise	Common Stock	8,394	$0.00	--
Tax Withholding	Common Stock	2,875	$5.70	$16K

Holdings After Transaction: Restricted Stock Units — 125,208 shares (Direct); Common Stock — 66,678.158 shares (Direct)

Footnotes (1)

1. The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSUs") were awarded. On March 31, 2026, the Reporting Person was granted 125,208 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Each RSU represents a contingent right to receive one share of Organon common stock. On March 31, 2023, the Reporting Person was granted 13,818 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. On March 31, 2025, the Reporting Person was granted 25,184 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nisita Vittorio

(Last) (First) (Middle)

C/O ORGANON & CO.

30 HUDSON STREET, FLOOR 33

(Street)

JERSEY CITY NEW JERSEY 07302

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Organon & Co. [ OGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Global Business Svcs

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		M		4,606	A	$0	66,678.158	D
Common Stock	03/31/2026		F		1,578	D	$5.7(1)	65,100.158	D
Common Stock	03/31/2026		M		8,394	A	$0	73,494.158	D
Common Stock	03/31/2026		F		2,875	D	$5.7(1)	70,619.158	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/31/2026		A		125,208		(2)	(2)	Common Stock	125,208	$0	125,208	D
Restricted Stock Units	(3)	03/31/2026		M			4,606	(4)	(4)	Common Stock	4,606	$0	0	D
Restricted Stock Units	(3)	03/31/2026		M			8,394	(5)	(5)	Common Stock	8,394	$0	16,790	D

Explanation of Responses:

1. The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSUs") were awarded.

2. On March 31, 2026, the Reporting Person was granted 125,208 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

3. Each RSU represents a contingent right to receive one share of Organon common stock.

4. On March 31, 2023, the Reporting Person was granted 13,818 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.

5. On March 31, 2025, the Reporting Person was granted 25,184 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

Remarks:

	/s/ Tarnetta V. Jones, as Attorney-in-Fact for Vittorio Nisita	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)